CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
alpha-lipoic acid and acetyl-L-carnitine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01054768
NCT01054768Phase 2Completed
CompareCT.gov

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

UCSF Benioff Children's Hospital Oakland·interventional·Posted Jan 22, 2010·Updated Aug 3, 2021

In Brief

A Phase 2 clinical trial evaluating alpha-lipoic acid and acetyl-L-carnitine and Control for Anemia, Sickle Cell. Completed, enrolled 37 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 22, 2010
Enrollment StartAug 1, 2009
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.4 years ago

Interventions

alpha-lipoic acid and acetyl-L-carnitinedrug

none to report

Controldrug

none to report